Breaking News Instant updates and real-time market news.

REGN

Regeneron

$371.68

-4.11 (-1.09%)

, TEVA

Teva

$42.96

-1.32 (-2.98%)

07:02
10/17/16
10/17
07:02
10/17/16
07:02

Regeneron says stops dosing in Phase 2b fasinumab study in chronic low back pain

REGN

Regeneron

$371.68

-4.11 (-1.09%)

TEVA

Teva

$42.96

-1.32 (-2.98%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

REGN Regeneron
$371.68

-4.11 (-1.09%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
TEVA Teva
$42.96

-1.32 (-2.98%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

TODAY'S FREE FLY STORIES

OXFD

Oxford Immunotec

$15.34

0.2 (1.32%)

16:45
06/22/17
06/22
16:45
06/22/17
16:45
Hot Stocks
Oxford Immunotec announces reimbursement decision for T-SPOT test in France »

Oxford Immunotec Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$25.90

-0.85 (-3.18%)

16:40
06/22/17
06/22
16:40
06/22/17
16:40
Syndicate
Evolent Health files to sell 4.5M shares of Class A common stock for holders »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.02 (1.17%)

16:34
06/22/17
06/22
16:34
06/22/17
16:34
Hot Stocks
Idera announces FDA orphan drug designation for IMO-2125 for melanoma treatment »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Fed Balance Sheet Level data reported »

Week of 6/21 Fed Balance…

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Money Supply M2 Weekly Change data reported »

Week of 6/12 Money Supply…

MGM

MGM Resorts

$33.25

0.29 (0.88%)

16:33
06/22/17
06/22
16:33
06/22/17
16:33
Hot Stocks
Breaking Hot Stocks news story on MGM Resorts »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

, BAC

Bank of America

$22.93

-0.2 (-0.86%)

16:32
06/22/17
06/22
16:32
06/22/17
16:32
Hot Stocks
All 34 banks exceed minimum requirements of Fed Stress Test »

Publicly traded banks…

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

BAC

Bank of America

$22.93

-0.2 (-0.86%)

C

Citi

$63.62

-0.21 (-0.33%)

WFC

Wells Fargo

$52.49

-0.49 (-0.92%)

JPM

JPMorgan

$87.02

-0.1 (-0.11%)

MS

Morgan Stanley

$44.61

-0.3 (-0.67%)

USB

U.S. Bancorp

$51.30

-0.7 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:30
06/22/17
06/22
16:30
06/22/17
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

16:27
06/22/17
06/22
16:27
06/22/17
16:27
Hot Stocks
YouTube developing 'VR180' video format, says team working with camera makers »

Alphabet's (GOOG)…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

LNVGY

Lenovo

$12.85

0.059 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

BBBY

Bed Bath & Beyond

$33.73

0.07 (0.21%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

NAT

Nordic American Tankers

$6.00

-0.02 (-0.33%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Syndicate
Breaking Syndicate news story on Nordic American Tankers »

Nordic American Tankers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JONE

Jones Energy

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Jones Energy exits Arkoma Basin with non-core asset sales »

Jones Energy announced …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

, CIR

CIRCOR

$58.20

2.98 (5.40%)

16:24
06/22/17
06/22
16:24
06/22/17
16:24
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, CIRCOR »

Gabelli reports 15.94%…

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

CIR

CIRCOR

$58.20

2.98 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:23
06/22/17
06/22
16:23
06/22/17
16:23
Hot Stocks
Bed Bath & Beyond says saw increased 'softness in transactions in stores' in Q1 »

At this time, Bed Bath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

CPE

Callon Petroleum

$9.69

-0.06 (-0.62%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Callon Petroleum appoints Correne S. Loeffler as Interim CFO »

Callon Petroleum has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 14

    Nov

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Bed Bath & Beyond repurchased approximately $127M of common stock in Q1 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SGH

Smart Global

$16.20

0.45 (2.86%)

16:20
06/22/17
06/22
16:20
06/22/17
16:20
Earnings
Smart Global sees Q4 EPS 62c-66c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
SYNNEX approves $300M share repurchase program »

SYNNEX has approved an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.97

0.54 (1.12%)

, HCA

HCA Holdings

$86.14

2.09 (2.49%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

AAL

American Airlines

$48.97

0.54 (1.12%)

HCA

HCA Holdings

$86.14

2.09 (2.49%)

PLNT

Planet Fitness

$23.95

0.38 (1.61%)

THC

Tenet

$18.89

1.21 (6.84%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

RAD

Rite Aid

$3.08

-0.11 (-3.45%)

WBA

Walgreens Boots Alliance

$76.37

-1.75 (-2.24%)

ORCL

Oracle

$50.30

3.97 (8.57%)

SPLS

Staples

$9.20

0.54 (6.24%)

JWN

Nordstrom

$47.48

1.4 (3.04%)

WB

Weibo

$72.25

-4.71 (-6.12%)

SCS

Steelcase

$14.10

-2.2 (-13.50%)

ACN

Accenture

$122.08

-5.03 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 07

    Jul

  • 18

    Jul

  • 23

    Aug

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
Bed Bath & Beyond reports Q1 SSS from customer-facing digital channels up 20%+ »

Comparable sales in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.96

1.62 (1.35%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
SYNNEX sees Q3 non-GAAP EPS $1.94-$2.02, consensus $1.92 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
Bed Bath & Beyond reports Q1 EPS 53c, consensus 66c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Earnings
SYNNEX reports Q2 non-GAAP EPS $2.08, consensus $1.79 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.